'Shotgun Wedding': Public, Private Drosophila Sequencing Agreement Should Speed Project, Ensure Accuracy

When J. Craig Venter proposed last May to use the "shotgun" technique to sequence Drosophila, many scientists doubted that blasting such a large genome into billions of base pairs, then reassembling it in one fell swoop would succeed.1 On the brink of the project's beginning, skepticism remains. But an agreement between Celera Genomics Corp. of Rockville, Md., and the University of California at Berkeley's Drosophila Genome Project Group, may render that uncertainty irrelevant. The Berkeley gr

Written byPaul Smaglik
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

When J. Craig Venter proposed last May to use the "shotgun" technique to sequence Drosophila, many scientists doubted that blasting such a large genome into billions of base pairs, then reassembling it in one fell swoop would succeed.1 On the brink of the project's beginning, skepticism remains.

But an agreement between Celera Genomics Corp. of Rockville, Md., and the University of California at Berkeley's Drosophila Genome Project Group, may render that uncertainty irrelevant. The Berkeley group will essentially draft both a cheat sheet and a safety net for the Celera project, by completing the fruit fly's gene map and by generating about 12,500 unfinished Bacterial Artificial Chromosome (BAC) end sequences. The Celera group, in addition to producing raw shotgun data, will sequence the Berkeley BAC ends.

Those two features will aid both teams in reassembling the Drosophila genome, notes Francis Collins, director of the National Human Genome Research Institute. "My ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies